

# Rikhia Chakraborty

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11121297/publications.pdf>

Version: 2024-02-01

32  
papers

1,363  
citations

567144

15  
h-index

580701

25  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1800  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without <i>BRAF</i> V600E. <i>Blood Advances</i> , 2022, 6, 4901-4904.	2.5	4
2	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. <i>Blood</i> , 2021, 137, 1777-1791.	0.6	25
3	<i>BRAF</i> V600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. <i>Nature Medicine</i> , 2021, 27, 851-861.	15.2	38
4	IFN- $\gamma$ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. <i>Blood Advances</i> , 2021, 5, 3457-3467.	2.5	23
5	MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a034892.	2.9	17
6	<i>BRAF</i> V600E vs cell of origin: what governs LCH?. <i>Blood</i> , 2021, 138, 1203-1204.	0.6	1
7	<i>BRAF</i> V600E or mutant <i>MAP2K1</i> human CD34+ cells establish Langerhans cell-like histiocytosis in immune-deficient mice. <i>Blood Advances</i> , 2020, 4, 4912-4917.	2.5	6
8	Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3603.	1.7	6
9	Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. <i>Blood Advances</i> , 2020, 4, 87-99.	2.5	25
10	The "Gatekeeper" Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia. <i>Blood</i> , 2019, 134, 5196-5196.	0.6	2
11	Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH. <i>Blood</i> , 2019, 134, 3602-3602.	0.6	0
12	TCR Repertoire Clonality Analysis and Transcriptome Analyses of Immune Infiltrates in Patients with Langerhans Cell Histiocytosis Can Define Prognostic Biomarkers for Future Therapeutic Development. <i>Blood</i> , 2019, 134, 3601-3601.	0.6	0
13	Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort. <i>Blood</i> , 2019, 134, 2773-2773.	0.6	0
14	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. <i>Cancer</i> , 2018, 124, 2607-2620.	2.0	73
15	RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. <i>Journal of Experimental Medicine</i> , 2018, 215, 319-336.	4.2	58
16	Inherited Genetic Risk Factors and Langerhans Cell Histiocytosis Relapse Events. <i>Blood</i> , 2018, 132, 4278-4278.	0.6	0
17	Whole Exome Analysis Reveals Key Genomic Differences between Sporadic and Endemic Pediatric Burkitt Lymphoma. <i>Blood</i> , 2018, 132, 4117-4117.	0.6	0
18	Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26321.	0.8	7

#	ARTICLE	IF	CITATIONS
19	p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6629-6639.	3.2	23
20	A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. <i>Blood</i> , 2017, 130, 2229-2232.	0.6	15
21	New somatic BRAF splicing mutation in Langerhans cell histiocytosis. <i>Molecular Cancer</i> , 2017, 16, 115.	7.9	37
22	Activating <i>MAPK1</i> (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. <i>Oncotarget</i> , 2017, 8, 46065-46070.	0.8	24
23	Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. <i>Blood</i> , 2016, 128, 2533-2537.	0.6	122
24	Inflammatory Plasma Proteins Predict Disease Severity and Response to Therapy in Patients with LCH. <i>Blood</i> , 2015, 126, 4072-4072.	0.6	0
25	A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis. <i>Blood</i> , 2015, 126, 4059-4059.	0.6	0
26	<i>BRAF-V600E</i> expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. <i>Journal of Experimental Medicine</i> , 2014, 211, 669-683.	4.2	346
27	Differentiating Skin-Limited and Multisystem Langerhans Cell Histiocytosis. <i>Journal of Pediatrics</i> , 2014, 165, 990-996.	0.9	77
28	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. <i>Blood</i> , 2014, 124, 3007-3015.	0.6	352
29	Mutually Exclusive Recurrent Somatic Mutations in MAP2K1 and BRAF Support a Central Role for ERK Activation in LCH Pathogenesis. <i>Blood</i> , 2014, 124, 5587-5587.	0.6	2
30	Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. <i>Haematologica</i> , 2013, 98, 533-537.	1.7	30
31	Plasma Biomarker Profiling In Langerhans Cell Histiocytosis: Risk-Stratifying The Inflammatory Storm. <i>Blood</i> , 2013, 122, 2854-2854.	0.6	0
32	Changes in Chemokine Receptor Expression of Regulatory T Cells After Ex Vivo Culture. <i>Journal of Immunotherapy</i> , 2012, 35, 329-336.	1.2	9